| Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial RD McBane II, WE Wysokinski, JG Le‐Rademacher, T Zemla, A Ashrani, ... Journal of thrombosis and haemostasis 18 (2), 411-421, 2020 | 482 | 2020 |
| The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical … PI Gonzalez‐Ericsson, ES Stovgaard, LF Sua, E Reisenbichler, Z Kos, ... The Journal of pathology 250 (5), 667-684, 2020 | 165 | 2020 |
| Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer Z Kos, E Roblin, RS Kim, S Michiels, BD Gallas, W Chen, KK van de Vijver, ... NPJ breast cancer 6 (1), 17, 2020 | 128 | 2020 |
| Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century S Yadav, D Karam, I Bin Riaz, H Xie, U Durani, N Duma, KV Giridhar, ... Cancer 126 (1), 26-36, 2020 | 126 | 2020 |
| Report on computational assessment of tumor infiltrating lymphocytes from the International Immuno-Oncology Biomarker Working Group M Amgad, ES Stovgaard, E Balslev, J Thagaard, W Chen, S Dudgeon, ... NPJ breast cancer 6 (1), 16, 2020 | 117 | 2020 |
| Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer RA Leon-Ferre, MY Polley, H Liu, JA Gilbert, V Cafourek, DW Hillman, ... Breast cancer research and treatment 167, 89-99, 2018 | 97 | 2018 |
| A contemporary review of male breast cancer: current evidence and unanswered questions RA Leon-Ferre, KV Giridhar, TJ Hieken, RW Mutter, FJ Couch, ... Cancer and Metastasis Reviews 37, 599-614, 2018 | 79 | 2018 |
| Apixaban and dalteparin in active malignancy associated venous thromboembolism R McBane II, CL Loprinzi, A Ashrani, JP Botero, RAL Ferre, S Henkin, ... Thrombosis and Haemostasis 117 (10), 1952-1961, 2017 | 75 | 2017 |
| Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide) C Xia, R Leon-Ferre, D Laux, J Deutsch, BJ Smith, M Frees, M Milhem Cancer chemotherapy and pharmacology 74, 691-697, 2014 | 71 | 2014 |
| Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial RD McBane, WE Wysokinski, J Le-Rademacher, AA Ashrani, AJ Tafur, ... Blood 132, 421, 2018 | 69 | 2018 |
| Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603) RA Leon-Ferre, PJ Novotny, EG Wolfe, SS Faubion, KJ Ruddy, D Flora, ... JNCI Cancer Spectrum 4 (1), pkz088, 2020 | 65 | 2020 |
| The landmark series: neoadjuvant chemotherapy for triple-negative and HER2-positive breast cancer RA Leon-Ferre, TJ Hieken, JC Boughey Annals of surgical oncology 28, 2111-2119, 2021 | 58 | 2021 |
| Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients N Norton, B Youssef, DW Hillman, A Nassar, XJ Geiger, BM Necela, H Liu, ... NPJ Breast Cancer 6 (1), 4, 2020 | 54 | 2020 |
| Management of hot flashes in women with breast cancer receiving ovarian function suppression RA Leon-Ferre, N Majithia, CL Loprinzi Cancer treatment reviews 52, 82-90, 2017 | 52 | 2017 |
| Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution ES Engelman, R Leon-Ferre, BG Naraev, N Sharma, S Sun, TM O’Dorisio, ... Pancreas 43 (2), 219-225, 2014 | 44 | 2014 |
| Characteristics and Spatially Defined Immune (micro) landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer JM Carter, MYC Polley, RA Leon-Ferre, J Sinnwell, KJ Thompson, ... Clinical Cancer Research 27 (20), 5628-5637, 2021 | 38 | 2021 |
| Advances in systemic therapies for triple negative breast cancer RA Leon-Ferre, MP Goetz Bmj 381, 2023 | 36 | 2023 |
| Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma RA Leon-Ferre, LA Kottschade, MS Block, RR McWilliams, RS Dronca, ... Melanoma Research 27 (4), 335-341, 2017 | 34 | 2017 |
| Roles of notch signaling in the tumor microenvironment AB D’assoro, R Leon-Ferre, EB Braune, U Lendahl International journal of molecular sciences 23 (11), 6241, 2022 | 31 | 2022 |
| Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials J Hudeček, L Voorwerk, M van Seijen, I Nederlof, M de Maaker, ... NPJ Breast Cancer 6 (1), 15, 2020 | 27 | 2020 |
